ANTI-PPARA CLONE 4G22 ZOOMAB« RABBIT MONOCLONAL (C15-1669-349)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 4G22 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects PPAR . It targets an epitope within 18 amino acids from the N-terminal half.

Immunogen

KLH-conjugated linear peptide corresponding to 18 amino acids from the N-terminal half of human Peroxisome proliferator-activated receptor . ( PPAR )

Application

Quality Control Testing

Evaluated by Western Blotting in C6 cell nuclear extract.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected PPAR in C6 cell nuclear extract.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected PPAR in Human Skeletal muscle tissue lysate..

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected PPAR in HEK293 cells.

Affinity Binding Assay: A representative lot of this antibody bound PPAR peptide with a KD of 7.3 x 10-6 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected PPAR in Human small intestine tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

Peroxisome proliferator-activated receptor alpha (UniProt: Q07869; also known as PPAR-alpha, Nuclear receptor subfamily 1 group C member 1) is encoded by the PPARA (also known as NR1C1, PPAR) gene (Gene ID: 5465) in human. PPARs are members of the nuclear hormone receptor family of transcription factors that mediate a variety of cellular processes, including glucose and lipid metabolism, inflammatory responses, and regulation of apoptotic cell death. They act by binding to specific peroxisome proliferator-response elements (PPREs) on target genes. Three forms of PPARs have been described, which are designated as α, β, and δ forms.  PPARα is expressed in skeletal muscle, liver, kidney, and endothelial cells and regulates lipoprotein metabolism. Its transcriptional activity is enhanced in the presence of insulin. It contains a DNA binding domain (aa 99-173) and a ligand-binding domain. It also has two NR C-4 type of zinc finger regions (aa 102-122 and 139-161) that bind to the regulator region of DNA when the receptor is activated. The ligand-binding domain has an extensive secondary structure of several α- helices and β-sheets. PPARα heterodimerizes with RXRA and this heterodimerization is required for its DNA binding and transactivation activity. Leukotriene B4 (LTB4) is shown to bind to PPARα  and induce transcription of genes of the ψ- and β-oxidation pathways and clofibrate that binds to PPAR alpha accelerates catabolism of LTB4 in granulocytes and macrophages. PPARα deficient mice show a prolonged inflammatory response when exposed to LTB4. GSK3-β is reported to phosphorylate serine 73 on PPARα alpha, which in turn increases ubiquitination and protein turnover and reduces its activity. Two isoforms of PPARα have been described that are produced by alternative splicing.  This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Rakhshandehroo, M., et al. (2010). PPAR Research. 2010; Article ID 612089; Van Raalte, DH., et al. (2004).Pharm. Res. 321(9); 1531-1538).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.